ArticleDiscover oncology2026
Multi-omics integration constructs a senescence-based prognostic model and identifies EIF4EBP1 as a therapeutic target in clear cell renal cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClear cell renal cell carcinoma (ccRCC) is a prevalent malignancy of the kidney, known for its aggressive growth and tendency to metastasize. Cellular senescence (CS), regarded as a characteristic feature of the natural aging process, is strongly linked to the initiation and advancement of several diseases. This research seeks to develop an integrated prognostic model utilizing senescence markers in ccRCC, with the goal of evaluating clinical outcomes and clarifying the tumor’s immune microenvironment.
methodsThe transcriptome profiles from ccRCC patients were acquired from TCGA database, and the senescence-related genetic model (SRGM) was developed through Cox proportional hazards analysis integrated with multiple machine learning approaches. In addition, immune microenvironment and drug sensitivity analysis were performed. EIF4EBP1 expression and its role in epithelial cell senescence were analyzed using single-cell RNA sequencing, spatial transcriptomics, and trajectory analysis. Finally, cellular experiments were conducted to confirm the role of silencing EIF4EBP1 in the biological behavior of ccRCC cells.
resultsThrough a comprehensive framework incorporating 117 machine learning algorithm combinations, we established an SRGM consisting of 9 genes. The optimal model was constructed using CoxBoost + StepCox[forward] and achieved a concordance index (C-index) of 0.743, demonstrating robust prognostic predictive capacity across independent datasets. EIF4EBP1 is a central gene in the model. Silencing EIF4EBP1 reduced cell migration, proliferation, and invasion, while inducing senescence-associated phenotypes and apoptosis in ccRCC cells. Additionally, it significantly enhanced the responsiveness of ccRCC cells to sunitinib treatment.
conclusionsIn summary, we developed a novel SRGM that effectively stratifies prognosis in ccRCC. Furthermore, EIF4EBP1 has been validated at the cellular level as a promising therapeutic target, providing innovative insights into the personalized treatment of ccRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.